¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"REC"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • rectilinear propagation
    Á÷Áø
  • rectitis
    Á÷Àå¿°, °ðâÀÚ¿°
  • rectoabdominal
    Á÷À庹ºÎ-, °ðâÀÚ¹è-
  • rectocele
    Á÷ÀåÅ»Ãâ, °ðâÀÚÅ»Ãâ(Áõ)
  • rectococcygeal muscle
    °ðâÀÚ²¿¸®±Ù, Á÷Àå¹Ì°ñ±Ù
  • rectococcypexy
    Á÷Àå¹Ì°ñ°íÁ¤(¼ú), °ðâÀÚ²¿¸®»À°íÁ¤(¼ú)
  • rectocolitis
    Á÷Àå°áÀå¿°, °ðâÀÚÀß·ÏâÀÚ¿°
  • rectocystotomy
    Á÷À广±¤Àý°³(¼ú), °ðâÀڹ汤Àý°³(¼ú)
  • rectofistula
    Á÷Àå»û±æ, °ðâÀÚ»û±æ, Á÷Àå·ç
  • rectogenital
    Á÷Àå»ý½Ä±â-, °ðâÀÚ»ý½Ä±â-
  • rectolabial
    Á÷ÀåÀ½¼ø-, °ðâÀÚÀ½¼ø-
  • rectolabial fistula
    Á÷ÀåÀ½¼ø´©°ø, °ðâÀÚÀ½¼ø»û±æ
  • rectoperineorrhaphy
    Á÷ÀåȸÀ½ºÀÇÕ(¼ú), °ðâÀÚ»ôºÀÇÕ(¼ú)
  • rectopexy
    Á÷Àå°íÁ¤(¼ú), °ðâÀÚ°íÁ¤(¼ú)
  • rectorectostomy
    Á÷ÀåÁ÷À忬°á(¼ú), °ðâÀÚ°ðâÀÚ¿¬°á(¼ú)
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • rectal palpation
    Á÷Àå³»ÃËÁø, °ðâÀÚÃËÁø
  • rectal prolapse
    °ðâÀÚÅ»ÃâÁõ, Á÷ÀåÅ»ÃâÁõ
  • rectal reflex
    °ðâÀڹݻç, Á÷Àå¹Ý»ç
  • rectal shelf
    °ðâÀÚ¼±¹Ý, Á÷Àå¼±¹Ý
  • rectal sinus
    °ðâÀÚ±¼, Á÷Àå±¼
  • rectal suppository
    Ç×¹®Á¾à
  • rectal swab
    °ðâÀÚ¸éºÀäÃë¹ý, Á÷Àåµµ¸»¹ý
  • rectal urgency
    º¯¸øÂüÀ½, º¯Àý¹Ú(Áõ)
  • rectal valve
    °ðâÀÚÆÇ¸·, Á÷ÀåÆÇ¸·
  • rectal venous plexus
    °ðâÀÚÁ¤¸Æ¾ó±â
  • rectalgia
    (¢¡proctalgia) °ðâÀÚÅëÁõ, Á÷ÀåÅëÁõ
  • rectangular coordinate
    Á÷°¢ÁÂÇ¥
  • rectangular hyperbola
    Á÷°¢½Ö°î¼±
  • rectectomy
    (¢¡proctectomy) °ðâÀÚÀýÁ¦(¼ú), Á÷ÀåÀýÁ¦(¼ú)
  • rectification
    ±³Á¤, Á¤·ù
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • recoil electron
    ¹ÝµµÀüÀÚ
  • recoil nucleus
    ¹ÝµµÇÙ
  • recoil proton
    ¹Ýµµ¾çÀÚ
  • recoil wave
    ºÒ±ÔÄ¢ÆÄ(ÝÕЮöÎ÷î).
  • recollection
    ȸ»ó, »ó±â(ßÌÑÃ)
  • recoloring
    º¹»ö(ÜÖßä).
  • recombinant
    Àç°áÇÕÀÇ
  • recombinant
    ˍ禂͟.
  • recombinant
    ÀçÁ¶ÇÕ±ÕÁÖ
  • recombinant antigen
    ÀçÁ¶ÇÕ Ç׿ø
  • recombinant DNA
    ÀçÁ¶ÇÕ DNA
  • recombinant vaccine
    ÀçÁ¶ÇÕ¹é½Å.
  • recombinants
    ÀçÁ¶ÇÕÇü
  • recombination
    ÀçÁ¶ÇÕ.
  • recombination
    Àç°áÇÕ(î¢Ì¿ùê).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • recessus sacculi ³ª
    ¿øÇüÁÖ¸Ó´Ï¿À¸ñ, ±¸Çü³¶ÇÔ¿ä(Ϲû¡Ò¥ùèèê).
  • recessus sphenoethmoidalis ³ª
    Á¢Çü»ç°ñ¿À¸ñ, Á¢»çÇÔ¿ä(ïÊÞèùèèê).
  • recessus sphericus ³ª
    µÕ±Ù¿À¸ñ, ±¸Çü³¶ÇÔ¿ä(Ϲû¡Ò¥ùèèê).
  • recessus subhepatici ³ª
    °£¾Æ·¡¿À¸ñ, °£ÇÏÇÔ¿ä(ÊÜù»ùèèê).
  • recessus subphrenici ³ª
    Ⱦ°Ý¸·¾Æ·¡¿À¸ñ, Ⱦ°ÝÇÏÇÔ¿ä(üô̰ù»ùèèê).
  • recessus subpopliteus ³ª
    ¿À±Ý±Ù¾Æ·¡ÁÖ¸Ó´Ï, ½½¿Í±ÙÇÏÇÔ¿ä(ã£èÀÐÉù»ùèèê).
  • recessus triangularis ³ª
    »ï°¢¿À¸ñ, »ï°¢ÇÔ¿ä(ß²ÊÇùèèê).
  • recessus utriculi ³ª
    Ÿ¿øÁÖ¸Ó´Ï¿À¸ñ, ŸÇü³¶ÇÔ¿ä(NCû¡Ò¥ùèèê).
  • recessus vestibulo cochleare ³ª
    ÀüÁ¤´ÞÆØÀÌÇÔ¿ä, ÀüÁ¤¿Í¿ìÇÔ¿ä(îñïÔèÄéÚùè èê).
  • recessus zygomaticus ³ª
    ±Ç°ñ¿À¸ñ, Çù°ñ¿Í( ÍéèÀ).
  • recessus ³ª
    ¿À¸ñ, ÇÔ¿ä.
  • recipient
    ¼ö¿ëÀÚ, ¹Þ´ÂÀÚ, ÇÇÀü´ÞÀÚ
  • recipiomotor
    ¿îµ¿Ãæ°Ý¼ö¿ëÀÇ.
  • reciprocal anchorage
    »ó¹Ý°íÁ¤(ßÓÚãͳïÒ), ±³Á¤(Îìïá).
  • reciprocal articulation
    »óÈ£ °üÀý(ßÓû»Î¼ï½), »ó°ü °üÀý(ßÓμμï½).
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
receptors, laminin Glycoprotein molecules on the surface of cells that react with or bind to laminin whose function allows the binding of epithelial cells to the basement membrane. The molecular weight of this high-affinity receptor is 67 kD.
(12 Dec 1998)
receptors, ldl Receptors on the plasma membrane of nonhepatic cells that specifically bind ldl. The receptors are localised in specialised regions called coated pits. Hypercholesteraemia is caused by an allelic genetic defect of three types: 1) receptors do not bind to ldl; 2) there is reduced binding of ldl; and 3) there is normal binding but no internalization of ldl. In consequence, entry of cholesterol esters into the cell is impaired and the intracellular feedback by cholesterol on 3-hydroxy-3-methylglutaryl CoA reductase is lacking.
(12 Dec 1998)
receptors, leukocyte-adhesion Family of proteins associated with the capacity of leukocytes, including lymphocytes, monocytes, and neutrophils, to adhere to each other and to certain substrata, e.g., the c3bi component of complement. Members of this family are the lymphocyte function-associated antigen-1 (lfa-1), the macrophage-1 antigen (mac-1), and the antigen p150,95 or p150,95 leukocyte adhesion protein. They all share a common beta-subunit which is the CD18 antigen. All three of the above antigens are absent in inherited leukocyte-adhesion deficiency syndrome, which is characterised by recurrent bacterial infections, impaired pus formation, and wound healing as well as abnormalities in a wide spectrum of adherence-dependent functions of granulocytes, monocytes, and lymphoid cells.
(12 Dec 1998)
receptors, leukotriene Cell-surface receptors that bind leukotrienes with high affinity and trigger intracellular changes influencing the behaviour of cells. The leukotriene receptor subtypes have been tentatively named according to their affinities for the endogenous leukotrienes ltb4, ltc4, ltd4, and lte4.
(12 Dec 1998)
receptors, leukotriene b4 A class of cell surface leukotriene receptors with a preference for leukotriene b4. Leukotriene b4 receptor activation influences chemotaxis, chemokinesis, adherence, enzyme release, oxidative bursts, and degranulation in polymorphonuclear leukocytes. There are at least two subtypes of these receptors. Some actions are mediated through the inositol phosphate and diacylglycerol second messenger systems.
(12 Dec 1998)
receptors, lh Those protein complexes or molecular sites on the surfaces and cytoplasm of gonadal cells that bind luteinizing or chorionic gonadotropic hormones and thereby cause the gonadal cells to synthesise and secrete sex steroids. The hormone-receptor complex is internalised from the plasma membrane and initiates steroid synthesis.
(12 Dec 1998)
receptors, lhrh Receptors with a 6-kD protein on the surfaces of cells that secrete lh or fsh, usually in the adenohypophysis. Lhrh binds to these receptors, is endocytosed with the receptor and, in the cell, triggers the release of lh or fsh by the cell. These receptors are also found in rat gonads. Inhibin prevents the binding of gnrh to its receptors.
(12 Dec 1998)
receptors, lipoprotein Cell surface proteins that bind lipoproteins with high affinity. Lipoprotein receptors in the liver and peripheral tissues mediate the regulation of plasma and cellular cholesterol metabolism and concentration. The receptors generally recognise the apolipoproteins of the lipoprotein complex, and binding is often a trigger for endocytosis.
(12 Dec 1998)
receptors, lymphocyte homing Cell surface glycoproteins on lymphocytes and other leukocytes that mediate adhesion to specialised blood vessels called high endothelial venules. Several different classes of lymphocyte homing receptors have been identified, and they appear to target different surface molecules (addressins) on high endothelial venules in different tissues. The adhesion plays a crucial role in the trafficking of lymphocytes.
(12 Dec 1998)
receptors, macrophage colony-stimulating factor Glycoproteins of mw 165 kD which are encoded by the c-fms proto-oncogene. The binding of csf-1 to its receptors activates an intrinsic tyrosine kinase activity resulting in autophosphorylation of the receptors on tyrosine, rapid receptor down-regulation, and phosphorylation of as yet unidentified physiologic substrates that initiate a mitogenic response.
(12 Dec 1998)
receptors, metabotropic glutamate Cell surface proteins that bind glutamate and act through g-proteins to influence second messenger systems. Several types of metabotropic glutamate receptors have been cloned. They differ in pharmacology, distribution, and mechanisms of action.
(12 Dec 1998)
receptors, mineralocorticoid Cytoplasmic proteins that specifically bind mineralocorticoids and mediate their cellular effects. The receptor with its bound ligand acts in the nucleus to induce transcription of specific segments of DNA. Mineralocorticoids were named for their actions on extracellular electrolyte concentrations. The most important example is aldosterone.
(12 Dec 1998)
receptors, mitogen Glycoprotein molecules on the surface of b- and T-lymphocytes, that react with molecules of antilymphocyte sera, lectins, and other agents which induce blast transformation of lymphocytes.
(12 Dec 1998)
receptors, muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for muscarine over nicotine. There are several subtypes (usually m1, m2, m3...) that are characterised by their cellular actions, pharmacology, and molecular biology.
(12 Dec 1998)
receptors, n-methyl-d-aspartate A class of ionotropic glutamate receptors characterised by affinity for n-methyl-d-aspartate. Nmda receptors have an allosteric binding site for glycine which must be occupied for the channel to open efficiently and a site within the channel itself to which magnesium ions bind in a voltage-dependent manner. The positive voltage dependence of channel conductance and the high permeability of the conducting channel to calcium ions (as well as to monovalent cations) are important in excitotoxicity and neuronal plasticity.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 5 ÆäÀÌÁö: 10
  • Receptor, Galanin, Type 3 - »õâ A galanin receptor subtype with high affinity for GALANIN-LIKE PEPTIDE and low affinity for full length GALANIN and galanin peptide fragments.
    Synonyms : GALR3 Galanin Receptor, Galanin-3 Receptor, Galanin 3 Receptor, Galanin Receptor, GALR3, Receptor, Galanin-3
  • Receptor, IGF Type 1 - »õâ A protein-tyrosine kinase receptor that is closely related in structure to the INSULIN RECEPTOR. Although commonly referred to as the IGF-I receptor, it binds both IGF-I and IGF-II with high affinity. It is comprised of a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precusor protein. The beta subunit contains an intrinsic tyrosine kinase domain.
    Synonyms : IGF-1 Receptor, Insulin-Like-Growth Factor I Receptor, Receptor, IGF Type 1 alpha Subunit, Receptor, IGF Type 1 beta Subunit, Receptors, IGF-1, Receptors, Insulin-Like-Growth Factor I, IGF 1 Receptor, IGF I Receptor, IGF-1 Receptors, Receptor, IGF I
  • Receptor, IGF Type 2 - »õâ A receptor that is specific for IGF-II and mannose-6-phosphate. The receptor is a 250-kDa single chain polypeptide which is unrelated in structure to the type 1 IGF receptor (RECEPTOR, IGF TYPE 1) and does not have a tyrosine kinase domain.
    Synonyms : IGF-2 Receptor, Insulin-Like-Growth-Factor II Receptor, Mannose-6-Phosphate Receptor, Receptors, IGF-2, Receptors, Insulin-Like Growth Factor II, IGF 2 Receptor, IGF II Receptor, IGF-2 Receptors, Insulin Like Growth Factor II Receptor, Receptor, IGF II
  • Receptor, Insulin - »õâ A cell surface receptor for INSULIN. It is comprised of a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precusor protein. The receptor contains an intrinsic tyrosine kinase domain that is located within the beta subunit. Activation of the receptor by INSULIN results in numerous metabolic changes including increased uptake of GLUCOSE into the LIVER; MUSCLE; and ADIPOSE TISSUE.
    Synonyms : Insulin Receptor alpha Chain, Insulin Receptor beta Chain, Insulin-Dependent Tyrosine Protein Kinase, Receptors, Insulin, Insulin Receptor Protein Tyrosine Kinase, Insulin Receptors
  • Receptor, Interferon alpha-beta - »õâ A ubiquitously expressed heterodimeric receptor that is specific for both INTERFERON-ALPHA and INTERFERON-BETA. It is composed of two subunits referred to as IFNAR1 and IFNAR2. The IFNAR2 subunit is believed to serve as the ligand-binding chain; however both chains are required for signal transduction. The interferon alpha-beta receptor signals through the action of JANUS KINASES such as the TYK2 KINASE.
    Synonyms : IFN-alphaR, IFN-alphabetaR, IFNAR1 Subunit, Interferon alpha-beta Receptor, IFNAR2 Subunit, Interferon alpha-beta Receptor, IFNAR2.1 Subunit, Interferon alpha-beta Receptor, IFNAR2.2 Subunit, Interferon alpha-beta Receptor, Interferon alpha Receptor
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 5 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
receiver (Rx): An electronic device that receives the signal from the transmitter.
Ãâó: www.geocities.com/h3ath3ry/dictionary.htm
recur To occur again.
Ãâó: www.stjude.org/glossary
reconstructive surgery Surgery that is done to reshape or rebuild (reconstruct) a part of the body changed by previous surgery.
Ãâó: www.stjude.org/glossary
recurrence Cancer that has returned after a period of time during which the cancer could not be detected. The cancer may come back to the same place as the original (primary) tumor or to another place in the body. Also called recurrent cancer.
Ãâó: www.stjude.org/glossary
receptor A molecule inside or on the surface of a cell that binds to a specific substance and causes a specific physiologic effect in the cell.
Ãâó: www.stjude.org/glossary
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • reciprocally
    ¼­·Î
  • reciprocate
    ±³È¯ÇÏ´Ù; º¸´äÇÏ´Ù
  • reciprocate
    ¿Õº¹¿îµ¿À» ½ÃŰ´Ù;±³È¯ÇÏ´Ù;ÁÖ°í ¹Þ´Ù;º¸´äÇÏ´Ù;´ä·ÊÇÏ´Ù;º¸º¹ÇÏ´Ù;º¸´ä(´ä·Ê)ÇÏ´Ù;º¸º¹ÇÏ´Ù;´ëÀÀÇÏ´Ù;ÀÏÄ¡ÇÏ´Ù;¿Õº¹ ¿îµ¿À» ÇÏ´Ù
  • reciprocating engine
    ¿Õº¹±â°ü
  • reciprocation
    ±³È¯
  • reciprocation
    ±³È¯;º¸´ä;º¸º¹;¿Õº¹ ¿îµ¿;´ëÀÀ
  • reciprocator
    º¸´äÇÏ´Â »ç¶÷;¿Õº¹±â°ü
  • reciprocity
    »óÈ£°ü°è
  • reciprocity
    »óÈ£ °ü°è(»óÅÂ);»óÈ£ ÀÛ¿ë;±³È¯;»óÈ£ ÀÌÀÍ(Àǹ«,±Ç¸®);È£ÇýÁÖÀÇ
  • recision
    Ãë¼Ò;Æó±â(¹ý·üµîÀÇ)
  • recitable
    À¼±â¿¡ ¾Ë¸ÂÀº;»ó¼ú ÇÒ ¼ö ÀÖ´Â
  • recital
    À̾߱â; º¸°í; ¾Ï¼Û; »ó¼ú(»ó¼ú)
  • recital
    (À½¾Ç.¹«¿ëÀÇ 1ÀÎ ¶Ç´Â ¼Ò¼öÀÇ)¸®»çÀÌÆ²;¿¬ÁÖȸ;µ¶ÁÖ(µ¶Ã¢)ȸ;(½Ã µîÀÇ)³¶¼Û;³¶µ¶(ȸ);»ó¼ú;ÀÚ¼¼ÇÑ ¼³¸í;À̾߱â;(¹ý·ü ¹®¼­ÀÇ)»ç½ÇÀÇ ¼³¸í ºÎºÐ;ºñ°í ºÎºÐ(Áõ¼­µîÀÇ);~ist
  • recitation
    ³¶¼Û
  • recitation
    »ó¼ú;¾Ï¼Û;³¶¼Û;¾Ï¼Û¹®;(º¹½À ±³Àç.°úÁ¦¿¡ °üÇÑ)±¸µÎ ¹Ýº¹(¾Ï¼Û,º¹Ã¢)(±³»ç¾Õ ¿¡¼­ÀÇ);±³½Ç °ú¾÷½Ã°£
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 12 ÆäÀÌÁö: 10
REC ready or willing to receive favorably
REC aphasia characterized by fluent but meaningless speech and severe impairment of the ability understand spoken or written words
REC in a receptive manner
REC willingness or readiness to receive esp impressions or ideas
REC willingness or readiness to receive esp impressions or ideas
REC an organ having nerve endings (in the skin or viscera or eye or ear or nose or mouth) that respond to stimulation
REC a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
REC a pause from doing something (as work)
REC an enclosure that is set back or indented
REC an arm off of a larger body of water (often between rocky headlands)
REC a small concavity
REC a state of abeyance or suspended business
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 5 ÆäÀÌÁö: 10
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
ÅëÇÕ°Ë»ö ¿Ï·á